Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
Curtiss
Frederic R
FR
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D000068717:Glatiramer Acetate; D017048:Health Care Costs; D006801:Humans; D007155:Immunologic Factors / Q000191:economics* / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000191:economics / Q000627:therapeutic use; D017059:Models, Econometric; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics*; D000069442:Natalizumab; D017063:Outcome Assessment, Health Care; D010349:Patient Compliance; D017060:Patient Satisfaction; D010455:Peptides / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D012107:Research Design; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a